Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43452-43471

  Patil, Vikas ^a   Pal, Jagriti ^a   Somasundaram, Kumaravel ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Cancer specific mutations; Exome and RNA sequencing; Gene fusions; Glioblastoma; RNA editing

Indexed keywords

COMPLEMENTARY DNA; RNA;

ARTICLE; ATRX GENE; EGFR GENE; EXOME; GENE EXPRESSION; GENE FUSION; GENETIC VARIABILITY; GLIOBLASTOMA CELL LINE; HTERT GENE; HUMAN; IDH1 GENE; INDEL MUTATION; MLL3 GENE; MLL4 GENE; NF1 GENE; PROMOTER REGION; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; RNA EDITING; RNA ISOLATION; RNA SEQUENCE; SETD2 GENE; SINGLE NUCLEOTIDE VARIATION; SPTA1 GENE; SRCAP GENE; TP53 GENE; TUMOR GENE; AMINO ACID SEQUENCE; BRAIN TUMOR; GENETICS; GLIOBLASTOMA; HIGH THROUGHPUT SEQUENCING; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; EXOME; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, RNA;

EID: 84952935440     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6171     Document Type: Article

References (97)

1. MLJ A. Malignant Cerebral Glioma (Neurosurgical Topics, 2). (Neurosurgical Topics, 2). 1990.
2. Ohgaki H and Kleihues P. The definition of primary and secondary glioblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:764-772.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10:459-466.
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA and Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & development. 2007; 21:2683-2710.
5. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455:1061-1068.
6. Meyerson M, Gabriel S and Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nature reviews Genetics. 2010; 11:685-696.
7. Robison K. Application of second-generation sequencing to cancer genomics. Briefings in bioinformatics. 2010; 11:524-534.
8. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013; 45:1141-1149.
9. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155:462-477.
10. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, Lee H, Merriman B and Nelson SF. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS genetics. 2010; 6:e1000832.
11. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y and Meltzer PS. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013; 73:4372-4382.
12. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder J, Cao Y, Mukhyala K, Selvaraj SK, Yu M, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nature biotechnology. 2015; 33:306-312.
13. http://www.illumina.com/content/dam/illumina-marketing/documents/products/technotes/technote_snp_caller_sequencing.pdf.
14. http://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/datasheet-truseq-rna-access.pdf.
15. Clark MJ, Chen R, Lam HY, Karczewski KJ, Chen R, Euskirchen G, Butte AJ and Snyder M. Performance comparison of exome DNA sequencing technologies. Nature biotechnology. 2011; 29:908-914.
16. Gu X and Li WH. The size distribution of insertions and deletions in human and rodent pseudogenes suggests the logarithmic gap penalty for sequence alignment. Journal of molecular evolution. 1995; 40:464-473.
17. http://www.broadinstitute.org/oncotator/.
18. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43:D805-811.
19. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483:603-607.
20. Martinez R, Schackert HK, Plaschke J, Baretton G, Appelt H and Schackert G. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme. Oncology. 2004; 66:395-403.
21. Adzhubei I, Jordan DM and Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20.
22. Kumar P, Henikoff S and Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4:1073-1081.
23. Poullet P, Lin B, Esson K and Tamanoi F. Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes. Mol Cell Biol. 1994; 14:815-821.
24. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331:435-439.
25. Herz HM, Hu D and Shilatifard A. Enhancer malfunction in cancer. Molecular cell. 2014; 53:859-866.
26. UniProt C. UniProt: a hub for protein information. Nucleic acids research. 2015; 43:D204-212.
27. Tanaka A, Weinel S, Nagy N, O'Driscoll M, Lai-Cheong JE, Kulp-Shorten CL, Knable A, Carpenter G, Fisher SA, Hiragun M, Yanase Y, Hide M, Callen J and McGrath JA. Germline mutation in ATR in autosomal-dominant oropharyngeal cancer syndrome. American journal of human genetics. 2012; 90:511-517.
28. Takayama K, Salazar EP, Lehmann A, Stefanini M, Thompson LH and Weber CA. Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D. Cancer research. 1995; 55:5656-5663.
29. Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4:44-57.
30. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC and Lempicki RA. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007; 35:W169-175.
31. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007; 7:165-168.
32. Molchadsky A, Rivlin N, Brosh R, Rotter V and Sarig R. p53 is balancing development, differentiation and dedifferentiation to assure cancer prevention. Carcinogenesis. 2010; 31:1501-1508.
33. Qin H, Yu T, Qing T, Liu Y, Zhao Y, Cai J, Li J, Song Z, Qu X, Zhou P, Wu J, Ding M and Deng H. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J Biol Chem. 2007; 282:5842-5852.
34. Tedeschi A and Di Giovanni S. The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep. 2009; 10:576-583.
35. Ferreira A and Kosik KS. Accelerated neuronal differentiation induced by p53 suppression. J Cell Sci. 1996; 109 :1509-1516.
36. Yang X, Klein R, Tian X, Cheng HT, Kopan R and Shen J. Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol. 2004; 269:81-94.
37. Yeudall WA, Wrighton KH and Deb S. Mutant p53 in cell adhesion and motility. Methods in molecular biology. 2013; 962:135-146.
38. Anaganti S, Fernandez-Cuesta L, Langerod A, Hainaut P and Olivier M. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Lett. 2011; 300:215-224.
39. Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C and Cance WG. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. BMC Cancer. 2013; 13:342.
40. Lee JG, Ahn JH, Jin Kim T, Ho Lee J and Choi JH. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals. Sci Rep. 2015; 5:12642.
41. Wawryk-Gawda E, Chylinska-Wrzos P, Lis-Sochocka M, Chlapek K, Bulak K, Jedrych M and Jodlowska-Jedrych B. P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 2014; 251:525-533.
42. Mollereau B and Ma D. The p53 control of apoptosis and proliferation: lessons from Drosophila. Apoptosis. 2014; 19:1421-1429.
43. Mercer WE, Avignolo C and Baserga R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol. 1984; 4:276-281.
44. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 1999; 13:607-619.
45. Amaral JD, Xavier JM, Steer CJ and Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010; 9:145-152.
46. Haupt S, Berger M, Goldberg Z and Haupt Y. Apoptosis-the p53 network. J Cell Sci. 2003; 116:4077-4085.
47. Amundson SA, Myers TG and Fornace AJ, Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene. 1998; 17:3287-3299.
48. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807-1812.
49. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American journal of pathology. 2009; 174:1149-1153.
50. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H and Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and biophysical research communications. 2009; 390:547-551.
51. Cohen AL, Holmen SL and Colman H. IDH1 and IDH2 mutations in gliomas. Current neurology and neuroscience reports. 2013; 13:345.
52. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:6021-6026.
53. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P and Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. Acta neuropathologica. 2013; 126:931-937.
54. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S and Ichimura K. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta neuropathologica. 2013; 126:267-276.
55. http://www.gencodegenes.org/releases/19.html.
56. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest. 2007; 117:2033-2035.
57. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561-566.
58. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310:644-648.
59. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH and Seo JS. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome research. 2012; 22:436-445.
60. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337:1231-1235.
61. Shah N, Lankerovich M, Lee H, Yoon JG, Schroeder B and Foltz G. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data. BMC genomics. 2013; 14:818.
62. Kim J, Lee Y, Cho HJ, Lee YE, An J, Cho GH, Ko YH, Joo KM and Nam DH. NTRK1 fusion in glioblastoma multiforme. PLoS One. 2014; 9:e91940.
63. Ge H, Liu K, Juan T, Fang F, Newman M and Hoeck W. FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics. 2011; 27:1922-1928.
64. Kim D and Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome biology. 2011; 12:R72.
65. Torres-Garcia W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, Berger MF, Weinstein JN, Getz G and Verhaak RG. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014; 30:2224-2226.
66. Sachdev R, Sieverding C, Flotenmeyer M and Antonin W. The C-terminal domain of Nup93 is essential for assembly of the structural backbone of nuclear pore complexes. Molecular biology of the cell. 2012; 23:740-749.
67. Ryan CM, Harries JC, Kindle KB, Collins HM and Heery DM. Functional interaction of CREB binding protein (CBP) with nuclear transport proteins and modulation by HDAC inhibitors. Cell cycle. 2006; 5:2146-2152.
68. De Silvestris M, D'Arrigo A and Borgese N. The targeting information of the mitochondrial outer membrane isoform of cytochrome b5 is contained within the carboxyl-terminal region. FEBS letters. 1995; 370:69-74.
69. Ghanta S, Grossmann RE and Brenner C. Mitochondrial protein acetylation as a cell-intrinsic, evolutionary driver of fat storage: chemical and metabolic logic of acetyllysine modifications. Critical reviews in biochemistry and molecular biology. 2013; 48:561-574.
70. Scott I, Webster BR, Li JH and Sack MN. Identification of a molecular component of the mitochondrial acetyltransferase programme: a novel role for GCN5L1. The Biochemical journal. 2012; 443:655-661.
71. Distler AM, Kerner J and Hoppel CL. Post-translational modifications of rat liver mitochondrial outer membrane proteins identified by mass spectrometry. Biochimica et biophysica acta. 2007; 1774:628-636.
72. Distler AM, Kerner J and Hoppel CL. Proteomics of mitochondrial inner and outer membranes. Proteomics. 2008; 8:4066-4082.
73. Currie E, Schulze A, Zechner R, Walther TC and Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell metabolism. 2013; 18:153-161.
74. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H and Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. The Journal of clinical investigation. 2010; 120:142-156.
75. Gott JM and Emeson RB. Functions and mechanisms of RNA editing. Annual review of genetics. 2000; 34:499-531.
76. Rosenberg BR, Hamilton CE, Mwangi MM, Dewell S and Papavasiliou FN. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nature structural & molecular biology. 2011; 18:230-236.
77. Wulff BE, Sakurai M and Nishikura K. Elucidating the inosinome: global approaches to adenosine-to-inosine RNA editing. Nature reviews Genetics. 2011; 12:81-85.
78. Mo F, Wyatt AW, Sun Y, Brahmbhatt S, McConeghy BJ, Wu C, Wang Y, Gleave ME, Volik SV and Collins CC. Systematic identification and characterization of RNA editing in prostate tumors. PLoS One. 2014; 9:e101431.
79. Levanon EY, Eisenberg E, Yelin R, Nemzer S, Hallegger M, Shemesh R, Fligelman ZY, Shoshan A, Pollock SR, Sztybel D, Olshansky M, Rechavi G and Jantsch MF. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nature biotechnology. 2004; 22:1001-1005.
80. Shoshan-Barmatz V, Ben-Hail D, Admoni L, Krelin Y and Tripathi SS. The mitochondrial voltage-dependent anion channel 1 in tumor cells. Biochimica et biophysica acta. 2015; 1848:2547-2575.
81. Peng Z, Cheng Y, Tan BC, Kang L, Tian Z, Zhu Y, Zhang W, Liang Y, Hu X, Tan X, Guo J, Dong Z, Liang Y, Bao L and Wang J. Comprehensive analysis of RNA-Seq data reveals extensive RNA editing in a human transcriptome. Nature biotechnology. 2012; 30:253-260.
82. Kume H, Hino K, Galipon J and Ui-Tei K. A-to-I editing in the miRNA seed region regulates target mRNA selection and silencing efficiency. Nucleic acids research. 2014; 42:10050-10060.
83. Davey P, Rauth AM, Mason L and Addy L. Spontaneous phenotypic and karyotypic progression in the SV40 transfected cell line SVG during prolonged passage in vitro. Journal of neuro-oncology. 1990; 8:13-22.
84. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS and Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001; 61:4956-4960.
85. http://support.illumina.com/downloads/bcl2fastq_conversion_software_184.html.
86. http://bio-bwa.sourceforge.net/.
87. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R and Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25:2078-2079.
88. http://broadinstitute.github.io/picard/.
89. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research. 2010; 20:1297-1303.
90. http://evs.gs.washington.edu/EVS.
91. http://www.1000genomes.org/.
92. http://www.ncbi.nlm.nih.gov/SNP/.
93. Anders S, Pyl PT and Huber W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015; 31:166-169.
94. Anders S and Huber W. Differential expression analysis for sequence count data. Genome biology. 2010; 11:R106.95. Ramaswami G, Lin W, Piskol R, Tan MH, Davis C and Li JB. Accurate identification of human Alu and non-Alu RNA editing sites. Nature methods. 2012; 9:579-581.
95. Ramaswami G, Lin W, Piskol R, Tan MH, Davis C and Li JB. Accurate identification of human Alu and non-Alu RNA editing sites. Nature methods. 2012; 9:579-581
96. Ramaswami G, Zhang R, Piskol R, Keegan LP, Deng P, O'Connell MA and Li JB. Identifying RNA editing sites using RNA sequencing data alone. Nature methods. 2013; 10:128-132.
97. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling. 2013; 6:pl1.